chemotherapy to prevent breast cancer recurrence

... University of Hamburg, Germany; 2 Imperial Cancer Research Fund Breast Cancer Biology Group, Guy’s Hospital, London, UK Mucin glycoproteins on breast cancer cells car ry shortened carbohydrate ... added, N-acetyl galactosamine is not extended, or is sialylated to form the cancer- related sialyl Tn epitope. Because of the shorter side chains, the peptide core of the cancer mucin is more ... high specificity to the MUC-1 of breast cancer cells. SM3 is being tested for its diagnostic value [10,11] and also has a high therapeutic potential. The minimum peptide a ntigen epitope to SM3 w as identified...

... education to teach students the knowledge, attitudes, and behavioral skills they need to prevent skin cancer. 4. Involve family members in skin cancer prevention efforts. 5. Include skin cancer prevention ... personal susceptibility to skin cancer are more likely to use sunscreen (98). However, teenag- ers who practice skin cancer prevention tend to only use sun- screen and to use it infrequently, ... D. Guidelines for School Programs To Prevent Skin Cancer Schools as Settings for Skin Cancer Prevention Efforts Epidemiologic data suggest that several skin cancers can be prevented if children and adolescents...

... src="data:image/png;base64,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 Breastcancer.org is a nonprofit organization dedicated to providing education and information on breast health and breast cancer. Developed for you by Your Guide to the Breast Cancer ... your doctor to determine which treatments are right for you. Your Guide to the Breast Cancer Pathology Report A report is written each time tissue is removed from the body to check for cancer. ... questions about a breast abnormality 6 ã Is the breast abnormality a cancer? 6 ã Is the breast cancer invasive? 7 ã How different are the cancer cells from normal cells? 9 ã How big is the cancer? 10 ã...

... American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. CA Cancer J Clin 2007;57;7-28. 10. American Cancer Society. Breast Cancer ... increasing risk factors for breast cancer such as a higher age of rst pregnancy. To date, the vast majority of developing countries, with few exceptions, are unable to make breast cancer treatment ... and the Caribbean Africa Regions Breast cancer Cervical cancer Ovarian cancer Corpus uteri cancer Colorectal cancer % of DALYs *percentage is based on all cancer deaths and DALYs lost Fi g u...

... early breast cancer and (b) late breast cancer. Table 2 . Summary of the results on the relationship between breast cancer and reproductive factors according to age at diagnosis Risk factor ... Shapiro S: Risk factors for breast cancer in Black women. JNCI 78:213-7, 1987. 12. Brinton LA, Schairer C, Hoover RN, Fraumeni JF : Menstrual factors and risk of breast cancer. Cancer Investigation ... World Cancer Research Fund. Food, Nutrition and the Prevention of Cancer: a global perspective. Washington, DC: American Institute for Cancer Research, 1997. 4. Stavraky K, Emmons S: Breast cancer...

... doses, x-rays are used to treat cancer. 24 Chemotherapy Chemotherapy uses drugs to kill cancer cells. It may be given to women with Stage I, II, III, or IV breast cancer. Chemotherapy may be ... used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) ... receptor tests: Some breast cancers need hormones to grow. ese cancers have hormone receptors for the hormones estrogen, progesterone, or both. If the hormone receptor tests show that the breast...

... Occupational cancer among women: where have we been and where are we going? Am J Ind Med 2003, 44:565–575. 45. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and breastfeeding: ... risk of breast cancer. Lancet 2002, 360:1044 – 1049. 47. Robert SA, Strombom I, Trentham-Dietz A, Hampton JM, McElroy JA, Newcomb PA, Remington PL: Socioeconomic risk factors for breast cancer: ... Gilbertson M, Beck M: Farm work in Ontario and breast cancer risk.InRural Women’s health. Edited by Leipert BD, Leach B, Thurston W. Toronto: University of Toronto Press, In press; 101– 121. 52. DeMatteo...

... well- being, and nine additional items specifically related to breast cancer. The nine breast cancer specific items include questions related to appearance, sexuality, treatment side effects, and stress/illness. ... in survival from breast cancer. Journal of Psychosomatic Research, 27, 77–83. Grandstaff, N.W. (1976). The impact of breast cancer on the family. In: J.M. Vaeth (Ed.), Breast cancer: Its impact ... 563–573. Quality of Life and Breast Cancer 515 six-month follow-up. Stanton and Snider (1993) found that cognitive avoidance/ denial was detrimental to women with breast cancer prebiopsy, postbiopsy,...

... follow-up (0 to 14, 15 to 29, 30 to 34, 35 to 39, 40 to 44, 45 to 49, 50 to 54, 55 to 59, 60 to 64, 65 to 69 and 70+) and calendar period of follow-up (1961 to 1965, , 2001 to 2005, 2006 to 2007. Case ... diagnosis 1961 to 1985 444 0.98 (0.87 to 1.10) 49 0.84 (0.59 to 1.19) 1986 to 1995 615 0.94 (0.86 to 1.04) 192 0.96 (0.82 to 1.13) 1996 to 2000 282 1.10 (0.95 to 1.27) 129 0.90 (0.73 to 1.10) 2001 to 2007 ... of breast cancer Cancer IRR* (95% CI) Age at immigration 0 to 14 835 0.85 (0.77 to 0.93) 15 to 34 5,276 1.02 (0.96 to 1.08) 35+ 1,702 Reference Duration of residence 0 to 4 660 0.88 (0.79 to...

... breast cancer who had also developed end ometrial cancer 25% to 28% of the deaths were due to endome- trial cancer, 32% to 35% to breast cancer (type of cancer death could not be distinguished between ... their breast cancer or between the diagnosis of the initial primary breast cancer and the subsequent endometrial cancer (except non-melanoma skin cancer, in situ cervical cancer or breast cancer) ... endometrial cancer after breast cancer during defined periods (NL (n = 765): 1978 to 1997; UK (n = 786): 1988 to 1996; US (n = 324): 1978 to 1993). The endometrial cancer diagnosis had to have occurred...

... Access to Care ã S25 Toronto Sunnybrook Regional Cancer Center, and Cancer Care Ontario, Toronto, Ontario, Canada; Martin Yaffe, PhD, Ontario Breast Screening Program, Toronto, Ontario, Canada; ... symp- tomatic breast cancers as well. In the United Kingdom, Stockton et al. (20) found that in the 1980s before the National Breast Screening Pro- gram began, the rate of advanced breast cancer ... of detecting occult breast cancer over symptomatic breast cancer. Insofar as increasing tumor size is associated with poorer outcomes, there is also an advantage for detecting symptomatic breast cancer at...

... major contributing factor to the development of breast cancer is decreased functional expression of breast cancer susceptibility gene 1, BRCA1. Another key contributor to tumorigenesis is hypoxia. ... chemotherapeutic drugs and tumor necrosis factor-related apoptosis- inducing ligand ⁄ Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63, 5390–5400. 21 Tomlinson GE, Chen TT-L, ... inhibi- tion of apoptosis. Hypoxia has been reported to inhibit apoptosis induced by tumor necrosis factor-related apoptosis- inducing ligand (TRAIL) [14,15], which selectively induces apoptosis in malignant,...

... [197], and hepatoma [198], have demonstrated cytotoxic effects at pharmacologically-achievable con- centrations. Enhancement of cytotoxicity of docetaxel, epirubicin, irinotecan, and 5-FU to a battery ... appear to be associated with its ability to prevent the endothelial dysfunction [83] associated with suppres- sion of proinflammatory chemokines [84], prevention of endothelial cell apoptosis ... 23:99-109. 76. Edgington TS, Mackman N, Fan ST, Ruf W: Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol 1992, 34(Suppl):S15-27. 77....

... [197], and hepatoma [198], have demonstrated cytotoxic effects at pharmacologically-achievable con- centrations. Enhancement of cytotoxicity of docetaxel, epirubicin, irinotecan, and 5-FU to a battery ... appear to be associated with its ability to prevent the endothelial dysfunction [83] associated with suppres- sion of proinflammatory chemokines [84], prevention of endothelial cell apoptosis ... mediated by direct tumor cytotoxicity or inhibi- tion of angiogenesis remains to be determined. Unfortu- nately, none of the ongoing trials of AA in cancer patients seek to address this issue [26-31]. Areas...